Andere talen Vaxart, Inc.

Aandelen

VXRT

US92243A2006

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,7097 ^USD	+7,79%		-6,07%	+23,90%

14/03	Vaxart, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
14/03	Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	27/03
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	14/03
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	07/03
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	06/03
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	06/03
Vaxart, Inc. Announces Chief Executive Officer Changes	06/03
Vaxart, Inc. Announces Management Appointments	06/03
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	05/02
North American Morning Briefing : Stock Futures -2-	01/02
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	19/01
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	19/01
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	16/01
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	16/01
Vaxart, Inc. Announces Management Change	16/01
Vaxart, Inc. Announces CEO Changes	16/01
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director	16/01
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	21/12
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vaxart, Inc.

Aandelen

VXRT

US92243A2006

Andere talen

Filters